QuidelOrtho Financial Statements
NASDAQ: QDELHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
QuidelOrtho revenue and earnings
In fiscal 2025, QuidelOrtho generated $2.73 billion in revenue, down 1.9% from fiscal 2024, its first annual decline since 2024. QuidelOrtho reported a net loss of $1.13 billion, compared with a loss of $2.05 billion a year earlier. Gross margin was 46.7% (up from 46.2%) and operating margin -33.7%.
Diluted earnings per share came in at -$16.69. Over the last 5 fiscal years, QDEL's revenue has grown at a 10.4% compound annual rate.
Summary generated from market data by MetaCap's automated system. Methodology
QuidelOrtho income statement (annual)
| Fiscal year (USD) | FY 20252025-12-28 | FY 20242024-12-29 | FY 20232023-12-31 | FY 20222023-01-01 | FY 20222022-01-02 | FY 20212021-01-03 |
|---|---|---|---|---|---|---|
| Revenue | 2.73B | 2.78B | 3.00B | 3.27B | 1.70B | 1.66B |
| Revenue growth (YoY) | -1.89% | -7.17% | -8.21% | +92.28% | +2.22% | — |
| Cost of Revenue | 1.46B | 1.50B | 1.50B | 1.33B | 420.30M | 305.40M |
| Gross Profit | 1.27B | 1.29B | 1.50B | 1.94B | 1.28B | 1.36B |
| Operating Expenses | 2.19B | 3.25B | 1.36B | 1.09B | 372.30M | 296.00M |
| Research & Development | 186.20M | 218.70M | 245.00M | 187.90M | 95.70M | 84.30M |
| Selling, General & Admin | 746.30M | 766.80M | 763.20M | 621.00M | 239.60M | 180.70M |
| Operating Income | -919.20M | -1.96B | 139.10M | 843.70M | 906.00M | 1.06B |
| Interest Expense | 177.60M | 163.50M | 147.60M | 75.70M | — | — |
| Other Income (Expense) | -5.80M | -7.10M | -20.60M | -8.10M | 100.00K | -1.10M |
| Pretax Income | -1.11B | -2.13B | -29.10M | 735.90M | 900.30M | 1.04B |
| Income Tax | 24.10M | -79.50M | -19.00M | 187.20M | 196.10M | 230.00M |
| Net Income | -1.13B | -2.05B | -10.10M | 548.70M | 704.20M | 810.30M |
| Net Income growth (YoY) | — | — | -101.84% | -22.08% | -13.09% | — |
| EPS (Basic) | -16.69 | -30.54 | -0.15 | 9.66 | 16.74 | 19.24 |
| EPS (Diluted) | -16.69 | -30.54 | -0.15 | 9.56 | 16.43 | 18.60 |
| Shares Outstanding (Basic) | 67.80M | 67.20M | 66.80M | 56.80M | 42.10M | 42.10M |
| Shares Outstanding (Diluted) | 67.80M | 67.20M | 66.80M | 57.40M | 42.90M | 43.60M |
| EBITDA | -477.20M | -1.51B | 596.30M | 1.13B | 958.70M | 1.11B |
| Gross Margin | 46.67% | 46.23% | 49.94% | 59.28% | 75.26% | 81.62% |
| Operating Margin | -33.67% | -70.46% | 4.64% | 25.83% | 53.34% | 63.81% |
| Net Margin | -41.45% | -73.74% | -34.00% | 16.80% | 41.46% | 48.76% |
This table shows 6 annual periods of QuidelOrtho's income statement, from FY 2025 back to FY 2021, across 20 line items including revenue, cost of revenue, gross profit. Values in USD; B = billions, M = millions. Fiscal periods follow QDEL's reporting calendar. What is a income statement?